

ERRATUM

The T2-FLAIR–mismatch sign as an imaging biomarker for *IDH* and 1p/19q status in diffuse low-grade gliomas: a systematic review with a Bayesian approach to evaluation of diagnostic test performance

TO THE READERSHIP: A clarification is needed in the article by Goyal et al. (Goyal A, Yolcu YU, Goyal A, et al. The T2-FLAIR–mismatch sign as an imaging biomarker for *IDH* and 1p/19q status in diffuse low-grade gliomas: a systematic review with a Bayesian approach to evaluation of diagnostic test performance. *Neurosurg Focus*. 2019;47[6]:E13).

The *Conclusions* section in the abstract and text states that the T2-FLAIR–mismatch sign is a highly specific marker of *IDH* mutation but not 1p/19 codeletion in diffuse low-grade gliomas, although there may be exceptions to this finding. To avoid confusion to the readership, we would like to amend it to read as follows: “The T2-FLAIR–mismatch sign was an insensitive but highly specific marker of *IDH* mutation and *IDHmut-Noncodel* profile, although significant exceptions may exist to this finding. Tumors with a positive sign may still be *IDHwt* or 1p/19q codeleted.”

The article has been corrected online as of May 1, 2020.

Anshit Goyal, MBBS
Mayo Clinic, Rochester, MN

INCLUDE WHEN CITING

DOI: 10.3171/2020.3.FOCUS19660a.

©AANS 2020, except where prohibited by US copyright law